Painful Diabetic Neuropathy Clinical Trial
Official title:
A Randomised, Double-Blind, Placebo-Controlled, Dose-Response Study of the Efficacy and Safety of MEDI7352 in Subjects With Painful Diabetic Neuropathy
Verified date | September 2023 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a study investigating the effect of MEDI7352 on chronic pain in patients with painful diabetic neuropathy. The study incudes a screening period of up to 45 days and a 12-week treatment period during which MEDI7352 or placebo will be administered intravenously (IV) on 6 occasions, with each dose separated by 14 days. There will be a 6-week follow-up period. Subjects will randomly be assigned to double-blind treatment with one of 4 dose levels of MEDI7352 or placebo
Status | Completed |
Enrollment | 112 |
Est. completion date | June 29, 2023 |
Est. primary completion date | June 29, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Key Inclusion criteria: - Male, or postmenopausal or surgically sterile female, 18 to 80 years of age - Body mass index of =42 kg/m2. - Chronic PDN persistent for 6 months or longer, not adequately controlled by standard of care treatments. - mean pain intensity score of =4, as measured on an 11-point (0-10) NRS - willing and able to discontinue all NSAID or COX-2 analgesic therapy - currently be taking medication for the treatment of PDN. Subjects should be taking at least one of the first-line medications (consistent with regional or local standard of care guidelines for PDN) Key Exclusion criteria: - Presence of other clinically significant neuropathy (eg, hereditary neuropathy, inflammatory neuropathy) or other clinically significant disorder (eg, nerve compression injury) involving abnormal peripheral sensation, with an aetiology that is considered to be distinct from that of PDN, and that is likely to interfere with assessment of peripheral nerve function, as judged by the investigator. - History of osteonecrosis, rapidly progressing OA, subchondral insufficiency fractures, neurogenic arthropathy, or analgesia-induced arthropathy. - Diagnosis of clinically significant OA currently affecting a major joint in the upper extremity (shoulder, elbow, or wrist) or lower extremity (hip, knee, or ankle) or axial spine; or other degenerative disease affecting any joint in subjects for whom, in the opinion of the investigator, there is an identified risk of osteonecrosis, rapidly progressing OA, subchondral insufficiency fractures, neurogenic arthropathy, or analgesia-induced arthropathy. - Chronic pain condition, other than PDN, that is likely to interfere with the evaluation of the subject's PDN pain, as judged by the investigator - Haemoglobin A1C greater than 8.5% (>8.5%). |
Country | Name | City | State |
---|---|---|---|
Denmark | Research Site | Gentofte | |
Hungary | Research Site | Balatonfüred | |
Hungary | Research Site | Budapest | |
Poland | Research Site | Bydgoszcz | |
Poland | Research Site | Gdansk | |
Poland | Research Site | Katowice | |
Poland | Research Site | Katowice | |
Poland | Research Site | Kraków | |
Poland | Research Site | Lublin | |
Poland | Research Site | Lublin | |
Poland | Research Site | Olsztyn | |
Poland | Research Site | Poznan | |
Poland | Research Site | Sochaczew | |
Poland | Research Site | Torun | |
Poland | Research Site | Warszawa | |
Poland | Research Site | Warszawa | |
Poland | Research Site | Wroclaw | |
Romania | Research Site | Bucuresti | |
Romania | Research Site | Calarasi | |
Romania | Research Site | Craiova | |
Romania | Research Site | Galati | |
Romania | Research Site | Targu-Mures | |
United Kingdom | Research Site | Barnsley | |
United Kingdom | Research Site | Blackpool | |
United Kingdom | Research Site | Cannock | |
United Kingdom | Research Site | Cardiff | |
United Kingdom | Research Site | Leeds | |
United Kingdom | Research Site | London | |
United Kingdom | Research Site | Manchester | |
United Kingdom | Research Site | Prescot | |
United Kingdom | Research Site | Stockton-on-Tees |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
Denmark, Hungary, Poland, Romania, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in the weekly average of the average daily pain scores | Change in the weekly average of the average daily pain scores from the baseline week to Week 12 of MEDI7352 compared to placebo, as measured on an 11-point (0-10) NRS. | from the baseline week to Week 12 | |
Secondary | Change in the weekly average of the average daily pain scores | Change in the weekly average of the average daily pain score, as measured on an 11-point (0-10) NRS, from baseline to Weeks 2, 4, 6, 8, and 10 of treatment and the week before the follow-up visit (week 17). | Weeks 2, 4, 6, 8, and 10 of treatment and the week before the follow-up visit (week 17). | |
Secondary | Change in the weekly average of the average daily pain scores | Percentage of subjects who have achieved =30% and =50% reductions in the weekly average of the average daily pain score from baseline during Weeks 4, 8, and 12 of treatment and the week before follow-up (week 17). | from baseline during Weeks 4, 8, and 12 of treatment and the week before follow-up (week 17). | |
Secondary | Change in Galer Neuropathic Pain Scale (NPS) | Change in Galer Neuropathic Pain Scale (NPS) from baseline to Days 28, 56, and 84 of treatment and the follow-up visit (week 18). | from baseline to Days 28, 56, and 84 of treatment and the follow-up visit (week 18) | |
Secondary | Change in Daily Sleep Interference Scale (DSIS) | Change in Daily Sleep Interference Scale (DSIS) from baseline to Days 28, 56, and 84 of treatment and the follow-up visit (week 18). | from baseline to Days 28, 56, and 84 of treatment and the follow-up visit (week 18) | |
Secondary | Proportion of subjects who have 'improved', 'much improved,' or 'very much improved' relative to baseline on the Patient Global Impression of Change (PGIC) | Proportion of subjects who have 'improved', 'much improved,' or 'very much improved' relative to baseline on the Patient Global Impression of Change (PGIC) on Days 28, 56, and 84 of treatment and the follow-up visit (week 18). | on Days 28, 56, and 84 of treatment and the follow-up visit (week 18). | |
Secondary | Change in the 36-item Short-Form Health Survey (SF-36) | Change in the 36-item Short-Form Health Survey (SF-36) from baseline to Day 84 of treatment. | from baseline to Day 84 of treatment | |
Secondary | Change in the amount of rescue medication used (in terms of dosage/day) | Change in the amount of rescue medication used (in terms of dosage/day) from baseline to Week 12 of treatment. | from baseline to Week 12 of treatment | |
Secondary | incidence of AEs and SAEs | from baseline up to 18 weeks | ||
Secondary | Area under the plasma concentration versus time curve of MEDI7352 | from baseline up to 18 weeks | ||
Secondary | Peak Plasma Concentration (Cmax) of MEDI7352 | from baseline up to 18 weeks | ||
Secondary | Summary of positive ADA against MEDI7352 | from baseline up to 18 weeks | ||
Secondary | To characterise the dose-response relationship of MEDI7352 on chronic pain in subjects with PDN | Change in the weekly average of the average daily pain scores from the baseline week to Week 12, as measured on an 11-point (0-10) NRS, versus dose. | from baseline up to 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04699734 -
Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy
|
N/A | |
Recruiting |
NCT05480228 -
EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA
|
Phase 2 | |
Recruiting |
NCT05476276 -
EPPIC-Net: Platform Protocol to Assess Treatments for Painful Diabetic Peripheral Neuropathy
|
Phase 2 | |
Unknown status |
NCT01125215 -
Capsaicin Nanoparticle in Patient With Painful Diabetic Neuropathy
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05937984 -
Treatment for Painful Diabetic Neuropathy
|
N/A | |
Recruiting |
NCT05080530 -
Vitamin D and Painful Diabetic Neuropathy
|
N/A | |
Completed |
NCT04005287 -
A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy
|
Phase 2 | |
Recruiting |
NCT03331614 -
An Evaluation of an SCCD on the Symptomatology of Painful DPN
|
N/A | |
Recruiting |
NCT03700528 -
The Development of Contextual Cognitive Behavioural Approach to PDN
|
N/A | |
Recruiting |
NCT04689984 -
The Benefits of Astaxanthin as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient
|
Phase 2/Phase 3 | |
Recruiting |
NCT04689971 -
The Benefits of Vitamin B Combination as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient
|
Phase 2/Phase 3 | |
Recruiting |
NCT04689958 -
The Benefits of Vitamin D 5000 IU as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient
|
Phase 2/Phase 3 | |
Completed |
NCT03749642 -
Trazodone/Gabapentin Fixed Dose Combination Products in Painful Diabetic Neuropathy
|
Phase 2 | |
Not yet recruiting |
NCT04087941 -
Efficacy and Safety of VM202 in Painful Diabetic Peripheral Neuropathy -The HOPES Trial
|
Phase 2 | |
Terminated |
NCT01129960 -
Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain
|
Phase 3 | |
Terminated |
NCT01056315 -
A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y
|
Phase 2 | |
Completed |
NCT00980746 -
Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy
|
Phase 2 | |
Completed |
NCT04786340 -
A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy
|
Phase 2 | |
Completed |
NCT03769675 -
Quantitative Assessment of Painful Diabetic Peripheral Neuropathy After High Frequency Spinal Cord Stimulation
|
N/A | |
Not yet recruiting |
NCT05118217 -
Microvascular Dysfunction in Diabetic Peripheral Neuropathy
|